Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation<\/em><\/p>\n New preclinical data demonstrate that a single dose of INHBE siRNA leads to lower inflammation of adipose tissue with strong suppression of pro-inflammatory M1 macrophages in visceral fat in DIO mice, highlighting potential mechanistic insights into the risk reduction for type 2 diabetes (T2D) and coronary artery disease (CAD) suggested by human genetics<\/em><\/p>\n CAMBRIDGE, Mass., June 20, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the presentation of preclinical data supporting WVE-007, its GalNAc-siRNA designed to silence INHBE mRNA, an obesity target with strong evidence from human genetics. The data demonstrate the ability of Wave\u2019s long-acting GalNAc-siRNA to reduce INHBE mRNA and Activin E protein, induce weight loss mainly through reduction of fat mass, and reduce pro-inflammatory macrophage recruitment in a diet-induced obese (DIO) mouse model. The data were highlighted today in an oral presentation at the American Diabetes Association\u2019s 85th<\/sup> Annual Scientific Sessions, taking place June 20 to 23, in Chicago.<\/p>\n \u201cThese exciting preclinical data highlighted in today\u2019s presentation both recapitulate human genetics findings and continue to support the potential of WVE-007 to drive weight reduction by reducing Activin E to induce lipolysis \u2013 or fat breakdown, preferentially reducing visceral fat, and decreasing inflammation of adipose tissue \u2013 all without impacting lean muscle mass. These data suggest a highly differentiated therapeutic profile with lower visceral fat, less insulin resistance and less inflammation, supporting potential for risk reduction of T2D, CAD and other obesity-related co-morbidities,\u201d said Erik Ingelsson, MD, PhD, Chief Scientific Officer. \u201cSilencing of INHBE is an entirely orthogonal mechanism from GLP-1s, which are centrally acting and impact the digestive system and central nervous system to decrease appetite. If these preclinical data translate in the clinic, WVE-007 has the potential to transform the obesity treatment paradigm by delivering healthy weight loss, preservation of muscle mass, and infrequent dosing of once or twice a year. We are evaluating WVE-007 in our ongoing INLIGHT clinical trial in adults living with overweight or obesity, and we are on track to deliver the first clinical data in the second half of this year.\u201d<\/p>\n Human genetics provides strong evidence for INHBE as a therapeutic target. Individuals who have a protective loss-of-function variant in one copy of the INHBE gene have a healthier cardiometabolic profile, including less abdominal fat, lower triglycerides, and lower risk of type 2 diabetes and cardiovascular disease. These heterozygous carriers also exhibit favorable associations with liver traits, including reductions in cT1 (reflecting liver inflammation and fibrosis) and ALT (reflecting liver damage), with no impact on liver fat.<\/p>\n The oral presentation titled, \u201csiRNA-INHBE Silencing in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile,\u201d highlighted results from studies in DIO mice that evaluated monotherapy (INHBE-siRNA alone) as well as combination (INHBE siRNA and semaglutide), and maintenance (INHBE siRNA when semaglutide treatment is discontinued) treatment settings. Key results are as follows:<\/p>\n The full presentation can be accessed by visiting \u201cScientific Presentations\u201d on the Investors section of the Wave Life Sciences website: https:\/\/ir.wavelifesciences.com\/events-publications\/scientific-presentations<\/a>.<\/p>\n About\u00a0Wave Life Sciences<\/strong> Forward-Looking Statements <\/strong> Contact:<\/strong> Investors:<\/strong>\n
\n
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave\u2019s RNA medicines platform, PRISM\u00ae<\/sup>, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave\u2019s diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington\u2019s disease, and Obesity, as well as several preclinical programs utilizing the company\u2019s broad RNA therapeutics toolkit. Driven by the calling to \u201cReimagine Possible\u201d, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave\u2019s science, pipeline and people, please visit www.wavelifesciences.com<\/a> and follow Wave on X<\/a> (formerly Twitter) and LinkedIn<\/a>.<\/p>\n
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding\u00a0our expectations for WVE-007 and the anticipated therapeutic benefits thereof; the anticipated timing of clinical data from our\u00a0INLIGHT clinical trial\u00a0of WVE-007; the novelty of our approach to silence INHBE\u00a0mRNA\u00a0in order to achieve healthy, sustainable weight loss and the potential for once- or twice-yearly dosing; the potential benefits of WVE-007 over existing obesity therapies; the potential of WVE-007\u2019s mechanism (INHBE) as a novel and unique obesity treatment to induce fat loss, preserve muscle, and drive weight loss;\u00a0 our understanding of our preclinical data for WVE-007 and our expectations of how such data will translate in humans; beliefs that Wave\u2019s portfolio of RNA medicines is differentiated, potentially best-in-class and potentially transformative; the broad potential of Wave\u2019s RNA medicines pipeline and oligonucleotide chemistry and any benefits that may arise as a result thereof. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled \u201cRisk Factors\u201d in Wave\u2019s most recent Annual Report on Form 10-K filed with the\u00a0Securities and Exchange Commission\u00a0(SEC), as amended, and in other filings Wave makes with the\u00a0SEC\u00a0from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.<\/p>\n
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827<\/p>\n
InvestorRelations@wavelifesci.com<\/a><\/p>\n
![\"\"](\"https:\/\/ml.globenewswire.com\/media\/ZGU3ODc4YjItZDVhMC00YzFjLWJiZTktMTU2NDRiZTdkZjcxLTEwMzE4NjAtMjAyNS0wNi0yMC1lbg==\/tiny\/Wave-Life-Sciences-USA-Inc-.png\")
\n <\/div>\n","protected":false},"excerpt":{"rendered":"